SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today an update to the ArteraAI Prostate Test ...

Nanostics has secured funding from Genome Canada and Genome Alberta to expedite the ClarityDX Prostate test integration into the standard of care for prostate cancer screening throughout the country.

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

CORRECTED January 18, 2024 // Editor's note: An earlier version of this story erroneously stated that Medicare has started covering use of the AI-based cancer test. Neither the company nor CMS ...